CO₂ laser and the genitourinary syndrome of menopause: a randomized sham-controlled trial

References

• Portman DJ, Gass LS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the study of Women's Sexual Health and the North American Menopause Society. Menopause 2014;21:1063–8
   PubMed Web of Science ®Google Scholar
• Nappi RE, Martini E, Cucinella L, et al. Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for healthy aging in women. Front Endocrinol 2019;10:1–11
   PubMed Web of Science ®Google Scholar
• Nappi RE, Lachowsky M. Menopause and sexuality: prevalence of symptoms and impact on quality of life. Maturitas 2009;63:138–41
   PubMed Web of Science ®Google Scholar
• Tadir Y, Gaspar A, Lev-Sagie A, Alexiades M, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017;49:137–59
   PubMed Web of Science ®Google Scholar
• Elia D, Gambacciani M, Berreni N, et al. Genitourinary syndrome of menopause (GSM) and laser VEL: a review. Horm Mol Biol Clin Investig 2019;41:1–21
   PubMed Web of Science ®Google Scholar
• Photiou L, Lin MJ, Dubin DP, Lenskaya V, Khorasani H. Review of non-invasive vulvovaginal rejuvenation. J Eur Acad Dermatol Venereol 2020;34:716–26
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Pitsouni E, Grigoriadis T, et al. Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results. Menopause 2019;26:248–55
   PubMed Web of Science ®Google Scholar
• Salvatore S, Pitsouni E, Del Deo F, Parma M, Athanasiou S, Candiani M. Sexual function in women suffering from genitourinary syndrome of menopause treated with fractionated CO2 laser. Sex Med Rev 2017;5:486–94
   PubMed Web of Science ®Google Scholar
• Streicher LF. Vulvar and vaginal fractional CO2 laser treatments for genitourinary syndrome of menopause. Menopause 2018;25:571–3
   PubMed Web of Science ®Google Scholar
• Rabley A, O'Shea T, Terry R, Byun S, Louis Moy M. Laser therapy for genitourinary syndrome of menopause. Curr Urol Rep 2018;19:83
   PubMed Web of Science ®Google Scholar
• Alexiades M. Device-based treatment for vaginal wellness. Semin Cutan Med Surg 2018;37:226–32
   PubMed Web of Science ®Google Scholar
• Shobeiri SA, Kerkhof MH, Minassian VA, Bazi T. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. Int Urogynecol J 2019;20:371–6
   Google Scholar
• FDA warns against use of energy-based devices to perform vaginal rejuvenation or vaginal cosmetic procedures: FDA safety communication. Date Issued: July 30, 2018. https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic
   Google Scholar
• Preti M, Vieira-Baptista P, Digesu GA, et al. The clinical role of LASER for vulvar and vaginal treatments in gynecology and female urology: an ICS/ISSVD best practice consensus document. Neurourol Urodyn 2019;38:1009–23
   PubMed Web of Science ®Google Scholar
• Persu C, Chapple CR, Cauni V, Gutue S, Geavlete P. Pelvic Organ Prolapse Quantification system (POP-Q) – a new era in pelvic organ prolapse staging. J Med Life 2011;4:75–81
   PubMedGoogle Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363–9
   PubMed Web of Science ®Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause 2015;22:845–9
   PubMed Web of Science ®Google Scholar
• Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther 2000;26:191–208
   PubMed Web of Science ®Google Scholar
• Zachariou A, Filiponi M, Kirana PS. Translation and validation of the Greek version of the female sexual function index questionnaire. Int J Impot Res 2017;29:171–4
   PubMed Web of Science ®Google Scholar
• Filocamo MT, Serati M, Li Marzi V, et al. The Female Sexual Function Index (FSFI): linguistic validation of the Italian version. J Sex Med 2014;11:447–53
   PubMed Web of Science ®Google Scholar
• Grigoriadis T, Athanasiou S, Giannoulis G, Mylona SC, Lourantou D, Antsaklis A. Translation and psychometric evaluation of the Greek short forms of two condition-specific quality of life questionnaires for women with pelvic floor disorders: PFDI-20 and PFIQ-7. Int Urogynecol J 2013;24:2131–44
   PubMed Web of Science ®Google Scholar
• Monticone M, Frigau L, Mola F, et al. Italian versions of the urogenital distress inventory-6 and incontinence impact questionnaire-7: translation and validation in women with urinary incontinence. Disabil Rehabil 2020;42:1–7
   PubMed Web of Science ®Google Scholar
• Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995;14:131–9
   PubMed Web of Science ®Google Scholar
• Lenhard W, Lenhard A. Calculation of effect sizes. Dettelbach (Germany): Psychometrica. 2016. Available from: //www.psychometrica.de/effect_size.html.
   Google Scholar
• Pieralli A, Fallani MG, Becorpi A, et al. Fractional CO2 laser for vulvovaginal atrophy (VVA) dyspareunia relief in breast cancer survivors. Arch Gynecol Obstet 2016;294:841–6
   PubMed Web of Science ®Google Scholar
• Pitsouni E, Grigoriadis T, Tsiveleka A, Zacharakis D, Salvatore S, Athanasiou S. Microablative fractional CO2-Laser therapy and the genitourinary syndrome of menopause: an observational study. Maturitas 2016;94:131–6
   PubMed Web of Science ®Google Scholar
• Sokol E, Karram M. An assessment of the safety and efficacy of a fractional CO2 laser system for the treatment of vulvovaginal atrophy. Menopause 2016;23:1102–7
   PubMed Web of Science ®Google Scholar
• Perino A, Cucinella G, Gugliotta G, et al. Is vaginal fractional CO2 laser treatment effective in improving overactive bladder symptoms in post-menopausal patients? Preliminary results. Eur Rev Med Pharmacol 2016;20:2491–7
   PubMed Web of Science ®Google Scholar
• Pitsouni E, Grigoriadis T, Falagas ME, Slavatore S, Athanasiou S. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas 2017;103:78–88
   PubMed Web of Science ®Google Scholar
• Athanasiou S, Pitsouni E, Falagas ME, Salvatore S, Grigoriadis T. CO2-laser for the genitourinary syndrome of menopause. How many laser sessions? Maturitas 2017;104:24–8
   PubMed Web of Science ®Google Scholar
• Cruz VL, Steiner ML, Pompei LM, Strufaldi R, et al. Randomized double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. Menopause 2018;25:21–8
   PubMed Web of Science ®Google Scholar
• Bourdel N, Alves J, Pickering G, Ramilo I, Roman H, Canis M. Systematic review of endometriosis pain assessment: how to choose a scale? Hum Reprod Update 2015;21:136–52
   PubMed Web of Science ®Google Scholar
• Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 2012;19:1130–9
   PubMed Web of Science ®Google Scholar
• Serati M, Bogani G, Di Dedda MC, et al. A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive. Eur J Obstet Gynecol Reprod Biol 2015;191:48–50
   PubMed Web of Science ®Google Scholar
• Origoni M, Cimmino C, Carminati G, et al. Postmenopausal vulvovaginal atrophy (VVA) is positively improved by topical hyaluronic acid application. A prospective observational study. Eur Rev Med Pharmacol Sci 2016;20:4190–5
   PubMed Web of Science ®Google Scholar
• Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885–9
   PubMed Web of Science ®Google Scholar
• Paraiso MFR, Ferrando CA, Sokol ER, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: the VeLVET Trial. Menopause 2020;27:50–6
   PubMed Web of Science ®Google Scholar
• Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 2010;17:281–9
   PubMed Web of Science ®Google Scholar
• Archer DF, Kimble TD, Lin FDY, Battucci S, Sniukiene V, Liu JH. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J Womens Health 2018;27:231–7
   PubMed Web of Science ®Google Scholar
• Simon JA, Archer DF, Kagan R, et al. Visual improvements in vaginal mucosa correlate with symptoms of VVA: data from a double-blind, placebo-controlled trial. Menopause 2017;24:1003–10
   PubMed Web of Science ®Google Scholar
• Archer DF, Goldstein SR, Simon JA, et al. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. Menopause 2019;26:611–21
   PubMed Web of Science ®Google Scholar